Skip directly to site content
Are You Still There?
Due to inactivity, you will be signed out in two minutes unless you click 'Continue'.

Are you still there?

Due to inactivity, you will be signed out in two minutes unless
you click 'Continue'.

Panel:   GN7F ARLN (Custom)
AR Bank # 0092 Pseudomonas aeruginosa
Study ID: CarbaNP-61

Biosample Accession #: SAMN04014933

mCIM Result: Positive    Carba NP Result: Positive
MLST: 235(Pasteur)


Panel:  Gram Negative Carbapenemase Detection (CarbaNP)  |  ARLN Verification (Custom)  |  Cefiderocol Verification (FDC) (Custom)  |  GN7F ARLN (Custom)  |  GAIHN (Custom)


MIC (μg/ml) Results and Interpretation
Drug MIC (μg/ml) INT
Amikacin >64R
Aztreonam 32R
Cefepime >32R
Cefiderocol 1S
Ceftazidime >128R
Ceftazidime/avibactam 1>16R
Ceftolozane/tazobactam 116R
Ciprofloxacin >8R
Colistin 31I
Doripenem >8R
Imipenem 64R
Imipenem+chelators 24---
Levofloxacin >8R
Meropenem >8R
Piperacillin/tazobactam 1>128R
Tobramycin >16R
S – I –R Interpretation (INT) derived from CLSI 2024 M100 S34
1 Reflects MIC of first component
2 Screen for metallo-beta-lactamase production [Rasheed et al. Emerging Infectious Diseases. 2013. 19(6):870-878]
3 Clinical and PK/PD data demonstrate colistin has limited clinical efficacy, even if an intermediate result is obtained. Alternative agents are strongly preferred. Colistin should be used in combination with one or more active antimicrobial agents. Consultation with an infectious disease specialist is recommended.
Device manufacturers and users of FDA cleared devices shall consult the FDA’s Antibacterial Susceptibility Test Interpretive Criteria       website for breakpoints recognized or recommended by FDA, and for information regarding FDA exceptions or additions to the applicable, recognized consensus standard.
Molecular Mechanisms of Resistance
CategoryGene
Aminoglycoside aac(3)-Ic, aac(6')-IB3, aadA6, ant(2")-la, aph(3')-IIb, aph(3')-VI
Beta-lactam IMP-14, OXA-10, OXA-488, PDC-35, VEB-9
Efflux pumps/Other mexA, mexE, SMR
Fosfomycin fosA
Phenicols/Bicyclomycins bcr1, cmlA5, floR2
Sulfonamides sul1
Tetracyclines tet(G)
 
Disclaimer:
The resistance mechanisms listed were identified by analysis of whole genome sequence using the ResFinder database (last updated June 2, 2016 and accessed on October 25, 2016). This analysis does not include mutations that may result in antibiotic resistance or resistance determinants added to newer versions of the ResFinder database or other antimicrobial resistance gene databases. Biosample accession numbers have been provided so that users can analyze the data on their own if so desired.
Propagation
MEDIUM
Medium: Trypticase Soy Agar with 5% Sheep Blood (BAP)

GROWTH CONDITIONS
Temperature: 35°C
Atmosphere: Aerobic

PROPAGATION PROCEDURE

Remove the sample vial to a container with dry ice or a freezer block. Keep vial on ice or block. (Do not let vial content thaw)

Open vial aseptically to avoid contamination

Using a sterile loop, remove a small amount of frozen isolate from the top of the vial

Aseptically transfer the loop to BAP

Use streak plate method to isolate single colonies

Incubate inverted plate at 35°C ± 2°C for 18-24 hrs.
Storage Temperature & Biosafety
STORAGE TEMPERATURE: -70°C

BIOSAFETY LEVEL: 2
Appropriate safety procedures should always be used with this material. Laboratory safety is discussed in the current publication of 'BioSafety in Microbiological and Biomedical Laboratories' from the U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, and National Institutes of Health.

Disclaimer:
This product is sent with the condition that you are responsible for its safe storage, handling, and use. All materials are the property of the Centers for Disease Control and Prevention (CDC) and have been made available on behalf of the Food and Drug Administration (FDA). This material is not for use in human subjects and may not be redistributed. While CDC uses reasonable efforts to include accurate and up-to-date information on this product sheet, CDC makes no warranties or representations as to its accuracy. CDC is not liable for damages arising from the misidentification or misrepresentation of cultures. Please refer to the Standard Letter Agreement (SLA) for further details regarding the use of this product.
Isolate History
Date Action Performed
09/12/23Comment was added
09/12/23Gene was added to 'IMP-14'
09/12/23Gene was removed from 'from '---' to ' IMP-1''
06/14/23Drug was removed: 'Gentamicin'
03/30/23Gene was added to 'SMR'
03/30/23Gene was added to 'mexE'
03/30/23Gene was added to 'mexA'
03/30/23Gene was added to 'sul1'
03/30/23Gene was added to 'fosA'
03/30/23Gene was added to 'floR2'
03/30/23Gene was added to 'cmlA5'
03/30/23Gene was added to 'bcr1'
03/30/23Gene was added to 'VEB-9'
03/30/23Gene was added to 'aph(3')-VI'
03/30/23Gene was added to 'aph(3')-IIb'
03/30/23Gene was added to 'ant(2")-la'
03/30/23Gene was added to 'aac(6')-IB3'
03/30/23Category was added: 'Efflux pumps/Other'
03/30/23Category was added: 'Sulfonamides'
03/30/23Category was added: 'Fosfomycin'
03/30/23Gene was removed from 'from '---' to ' cmlA1''
03/30/23Gene was removed from 'from '---' to ' aadB''
03/30/23Gene was added to 'PDC-35'
03/30/23Gene was added to 'OXA-488'
03/30/23Gene was added to 'IMP-1'
03/30/23Gene was added to 'PDC-35'
03/30/23Gene was added to 'OXA-488'
03/30/23Gene was added to 'IMP-1'
03/30/23Gene was removed from 'from '---' to ' VEB-1''
03/30/23Gene was removed from 'from '---' to ' PAO''
03/30/23Gene was removed from 'from '---' to ' OXA-50''
03/30/23Gene was removed from 'from '---' to ' IMP-14''
02/13/23MLST was updated: from' ST235(Pasteur)' to '235(Pasteur)'
12/19/22MLST was updated: from '---' to 'ST235(Pasteur)'
Top of Page
TOP